Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) reported on Wednesday that it has completed the acquisition of 35Pharma Inc, a Canada-based clinical-stage biopharmaceutical company focused on protein-based therapeutics. The deal includes HS235, a potential best-in-class treatment for pulmonary hypertension (PH), targeting the activin receptor signalling pathway.
HS235 is designed with enhanced selectivity, with the potential to reduce risks associated with existing therapies, including bleeding, pericardial effusion and increases in haemoglobin. Early clinical findings also suggest broader metabolic benefits, such as fat-selective weight loss, preservation of lean mass and improved insulin sensitivity, which could expand its clinical and commercial potential.
The acquisition strengthens GSK's research and development pipeline, complementing its focus on inflammatory and fibrotic drivers of chronic disease and supporting expansion across lung, liver and kidney indications. Proof-of-concept trials for HS235 are expected to begin shortly in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
Under the terms of the agreement, GSK acquired 100% of 35Pharma Inc. for USD950m. The global market for PH therapies is projected to reach USD18bn by 2032, with activin signalling inhibitors expected to account for approximately half of the market.
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
Bio-Thera reports promising BAT8008 - BAT1308 combination lung cancer clinical data at ESMO 2026
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
IHI and Bristol Myers Squibb launch initiative to expand cancer clinical trial access
Oracle partners AstraZeneca for AI-enabled healthcare innovation
GSK reports 61% response rate for investigational lung cancer drug
Omeros receives negative EU opinion on narsoplimab after re-examination
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Sophos IRB and ALCMI partner to support lung cancer research
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK